Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Angiotensin 1-7
Protective renin-angiotensin-system peptide studied for vascular, anti-inflammatory, and anti-fibrotic effects.
Tier Blow risk
02· Subject
Thymosin Beta-4
Actin-sequestering peptide with clinical data in ophthalmic wound healing and preclinical tissue repair.
Tier B-Cmed-high risk
01 · At a glance
| Decision factor | Angiotensin 1-7 | Thymosin Beta-4 | MOTS-c |
|---|---|---|---|
| Primary fit | longevity & anti-aging and immune support comparisons | tissue repair & recovery and immune support comparisons | fat loss & metabolism and longevity & anti-aging comparisons |
| Evidence | Tier B | Tier B-C | Tier C |
| Risk | low | med-high | high |
| Experience level | advanced | intermediate | advanced |
| Budget tier | premium | mid | premium |
| Administration route | intravenous, subcutaneous | topical, subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Angiotensin 1-7 | Thymosin Beta-4 | MOTS-c |
|---|---|---|---|
| Goal fit | Longevity & Anti-Aging, Immune Support | Tissue Repair & Recovery, Immune Support | Fat Loss & Metabolism, Longevity & Anti-Aging |
| What users compare it for | Potential endothelial, anti-inflammatory, and anti-fibrotic benefits in vascular and pulmonary research settings. | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. | Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice. |
| Onset timeline | Hemodynamic effects can appear quickly during infusion; structural outcomes are studied over longer periods. | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. | Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Angiotensin 1-7 | Thymosin Beta-4 | MOTS-c |
|---|---|---|---|
| Adverse effects | Main practical risk is hypotension or reflex tachycardia, especially in combination with other RAAS-active therapies. | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. | FDA: no identified human exposure data; significant immunogenicity/characterization risks. |
| Contraindications | Avoid in hypotension, volume depletion, and use caution with ACE inhibitors or ARBs. | Limited formal contraindication data. | No human data. |
| Interaction notes | Likely additive blood-pressure lowering with ACE inhibitors, ARBs, and other vasodilating strategies. | Limited formal interaction studies; treat as unknown outside studied settings. | Unknown. |
| Regulatory status | Investigational | Investigational | Not approved |
| FDA flag | No current flag noted | FDA compounding caution | FDA compounding caution |
| WADA status | Not listed | WADA S2 | Status unclear |
04 · Age & monitoring
| Decision factor | Angiotensin 1-7 | Thymosin Beta-4 | MOTS-c |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Angiotensin 1-7 | Thymosin Beta-4 | MOTS-c |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | $192.00 | €33.02 |
| Estimated monthly cost | No reliable estimate yet | $96.00 | €33.02 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | Angiotensin 1-7 | Thymosin Beta-4 | MOTS-c |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 1 listing | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.